文献速递乳腺癌

术前化疗对可手术乳腺癌女性结局的影响

Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.
PubMed 文献 · J Clin Oncol · 2023-01-01

在1523例原发可手术乳腺癌女性中,随机分配至术前或术后多柔比星联合环磷酰胺(AC)方案化疗。两组无病生存、无远处转移生存和总生存均无显著差异;术前化疗组更多患者接受肿块切除术和放疗。肿瘤对术前化疗的反应与结局相关,病理完全缓解者结局更好。

要点

  • 术前与术后AC化疗在DFS、DDFS和生存上无显著差异(P=.99、.70、.83)。
  • 术前化疗组肿块切除术加放疗比例高于术后组(67.8% vs 59.8%)。
  • 病理完全缓解者无复发生存率高于其他反应组(85.7% vs 76.9%、68.1%、63.9%,P<.0001)。

核心结论

  • 术前化疗与术后化疗同样有效,允许更多肿块切除术,适用于某些I期和II期患者,并可用于研究乳腺癌生物学。
  • 肿瘤对术前化疗的反应与结局相关,可作为评估化疗对微转移效果的替代指标;但了解 such 反应所提供的预后信息 beyond 术后治疗所获甚少。

研究设计与样本

  • 国家外科辅助乳腺和肠道项目(NSABP)B-18随机对照试验,纳入1523例原发可手术乳腺癌女性,随机分配至术前或术后AC方案化疗。

主要发现

  • 两组无病生存、无远处转移生存和总生存均无显著差异(P=.99、.70、.83)。
  • 术前组较术后组更多患者接受肿块切除术和放疗(67.8% vs 59.8%)。
  • 肿块切除术后同侧乳腺肿瘤复发率两组相似(7.9% vs 5.8%,P=.23)。
  • 病理完全缓解(pCR)者无复发生存率高于病理浸润癌(pINV)、临床部分缓解(cPR)和临床无缓解(cNR)者(85.7% vs 76.9%、68.1%、63.9%,P<.0001),控制基线预后变量后仍成立。
  • 术前模型(含乳腺肿瘤反应变量)对患者结局的区分度与术后模型大致相同。

临床怎么用

  • 术前化疗可用于某些I期和II期乳腺癌患者的治疗,并允许更多患者接受肿块切除术。
  • 肿瘤对术前化疗的反应与结局相关,但该反应信息在术后治疗所获预后信息之外提供有限。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine, in women with primary operable breast cancer, if preoperative doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan; AC) therapy yields a better outcome than postoperative AC therapy, if a relationship exists between outcome and tumor response to preoperative chemotherapy, and if such therapy results in the performance of more lumpectomies. PATIENTS AND METHODS: Women (1,523) enrolled onto National Surgical Adjuvant Breast and Bowel Project (NSABP) B-18 were randomly assigned to preoperative or postoperative AC therapy. Clinical tumor response to preoperative therapy was graded as complete (cCR), partial (cPR), or no response (cNR). Tumors with a cCR were further categorized as either pathologic complete response (pCR) or invasive cells (pINV). Disease-free survival (DFS), distant disease-free survival (DDFS), and survival were estimated through 5 years and compared between treatment groups. In the preoperative arm, proportional-hazards models were used to investigate the relationship between outcome and tumor response. RESULTS: There was no significant difference in DFS, DDFS, or survival (P = .99, .70, and .83, respectively) among patients in either group. More patients treated preoperatively than postoperatively underwent lumpectomy and radiation therapy (67.8% v 59.8%, respectively). Rates of ipsilateral breast tumor recurrence (IBTR) after lumpectomy were similar in both groups (7.9% and 5.8%, respectively; P = .23). Outcome was better in women whose tumors showed a pCR than in those with a pINV, cPR, or cNR (relapse-free survival [RFS] rates, 85.7%, 76.9%, 68.1%, and 63.9%, respectively; P < .0001), even when baseline prognostic variables were controlled. When prognostic models were compared for each treatment group, the preoperative model, which included breast tumor response as a variable, discriminated outcome among patients to about the same degree as the postoperative model. CONCLUSION: Preoperative chemotherapy is as effective as postoperative chemotherapy, permits more lumpectomies, is appropriate for the treatment of certain patients with stages I and II disease, and can be used to study breast cancer biology. Tumor response to preoperative chemotherapy correlates with outcome and could be a surrogate for evaluating the effect of chemotherapy on micrometastases; however, knowledge of such a response provided little prognostic information beyond that which resulted from postoperative therapy.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 2023. PMID: 36989610. doi:10.1200/JCO.22.02571

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。